IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced an investigation into Immix Biopharma on behalf of investors concerning potential violations of securities laws. The firm alleges the company may have issued misleading statements regarding the termination of Chief Medical Officer Richard Graydon, citing media reports that he was a fugitive living under a false identity.
Key figures
- Stock drop percent
- 14.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.